MRI Contrast Agents
5205 – 5217
control and took measurements with an absolute uncertainty in 1/T1 of
ꢀ1%.
38.18 ppm (CH2). One of the aromatic carbon nuclei was not observed,
probably because of severe line broadening.
Variable-temperature 17O NMR measurements were recorded at 2.1 T
3,9-Bis{6-[(4,5-dihydroimidazol-2-yl)aminoethyl]-10-[2-(dihydroxybora-
nylphenyl)]-2-oxo-3,6,9-triazadecyl}-6-carboxymethyl-3,6,9-triazaundeca-
nedioic acid (L1): Asolution containing 4 (0.654 g, 1.47 mmol), DTPA-bis-
anhydride (0.262 g, 0.73 mmol), and zeolite KAin absolute ethanol
(16 mL) was stirred at room temperature for 6 h. The suspension was fil-
tered and the solvent was removed under reduced pressure. The residue
was taken up in water and lyophilized to give L1 as a pale yellow solid
(0.840 g, 95%). 11B NMR (300 MHz; D2O; pH 9.0): d=ꢁ11.4 ppm;
1H NMR (300 MHz; D2O; pH 6.4): d=7.32–7.43 (m, 2H; ArH), 7.13–
7.24 (m, 4H; ArH), 7.03–7.13 (m, 2H; ArH), 3.87 (s, 4H; ArCH2), 3.47
(s, 8H; CH2 imidaz), 2.44–3.39 ppm (brs, 42H; CH2N); 13C NMR
(300 MHz; D2O; pH 6.4): d=180.37 (CO), 175.33 (CO), 171.94 (CO),
161.33 (CN3), 145.80 (very broad; CB), 141.79 (Carom), 131.69 (CHarom),
129.68 (CHarom), 129.04 (CHarom), 125.62 (CHarom), 60.97 (CH2), 60.56
(CH2), 56.08 (CH2 central), 54.35 (CH2), 54.17 (CH2), 53.94 (CH2), 53.72
(CH2), 52.15 (CH2), 51.35 (CH2), 45.47 (CH2), 44.13 (CH2 imidaz), 41.63
(CH2), 38.38 ppm (CH2). ESI-MS (positive): m/z: 1056.7 [M+3]+.
with a Jeol EX-90 instrument equipped with a 5-mm probe. AD O exter-
2
nal lock was used. Experimental settings: spectral width, 10000 Hz; 908
pulse, 7 ms; acquisition time, 10 ms; 1000 scans; no sample spinning.
Aqueous solutions containing 2.6% 17O isotope (Yeda) were used. The
transverse relaxation rates were calculated from the signal widths at half
the maximum signal height.
Fluorescence emission spectra were recorded with a Spex/Jobin-Yvon
Fluorlog 3 fluorescence spectrometer (Instruments s.a.).
Awell counter (DPC-Gamma C) with a 12 Compaq DeskPro compatible
computer was used for activity counting in the interaction studies.
Molecular modeling was performed with the HyperChem software (ver-
sion 7.5) and the MM+ force field was used.
Di-tert-butyl-nitrilo-2,2’,2’’-triethanamine-N,N’-dicarboxylate (1): Com-
pound 1 was prepared by the procedure proposed by Hamdaoui et al.[34]
1H NMR (300 MHz; CDCl3): d=5.36 (brs, 2H; NH or NH2), 3.19 (m,
4H; CH2), 2.76 (t, 2H; CH2), 2.57 (4H, t; CH2), 2.53 (m, 2H; CH2), 2.06
(brs, 2H; NH or NH2), 1.47 ppm (s, 18H; CH3); 13C NMR (75.48 MHz;
CDCl3): d=160.61 (OCON), 83.42 (Me3CO), 61.19 (CH2N), 58.50
(CH2N), 44.04 (CH2N), 42.95 (CH2N), 32.73 ppm ((CH3)3O).
3,9-Bis(tert-butyl-2-oxo-3,6-diazahexyl-N-carboxylate)-6-carboxymethyl-
3,6,9-triazaundecanedioic acid (5): Compound 5 was prepared by follow-
ing the procedure described by Carvalho et al.[35] 1H NMR (300 MHz;
CDCl3): d=3.75 (s, 4H; CH2CO), 3.64 (s, 4H; CH2CO), 3.62 (s, 2H;
CH2CO), 3.16–3.32 (m, 12H; CH2N), 3.10 (t, 4H; CH2N), 1.30 ppm (s,
18H; CH3); 13C NMR (300 MHz; CDCl3): d=173.82 (CO), 173.73 (CO
central), 170.58 (CO), 159.82 (O2CN), 82.65 (CMe3), 58.42 (CH2CO),
58.19 (CH2CO), 56.23 (CH2CO central), 53.15 (CH2N), 52.97 (CH2N),
40.89 (2CH2N), 29.38 ppm (CH3).
Di-tert-butyl-N’’-(4,5-dihydro-1H-imidazol-2-yl)-nitrilo-2,2’,2’’-triethan-
amine-N,N’-dicarboxylate (2): Asolution containing
23.57 mmol) and methylthioimidazoline hydroiodide
1
(8.167 g,
(5.812 g,
23.57 mmol) in EtOH (160 mL) was stirred at reflux (bath at 758C) for
5 h. The solvent was removed under reduced pressure and the resulting
red oil was used for the next step without further purification. 1H NMR
(300 MHz; CDCl3): d=3.78 (s, 4H; CH2 imidaz), 3.42 (m, 2H; CH2),
3.16 (m, 4H; CH2), 2.68 (t, 2H; CH2), 2.58 (t, 4H; CH2), 1.44 ppm (s,
18H; CH3); 13C NMR (75.48 MHz; CDCl3): d=160.07 (O2CN), 156.74
(CN3), 79.78 (OCMe3), 54.70 (CH2), 53.58 (CH2), 42.88 (CH2), 41.93
(CH2), 38.93 (CH2 imidaz), 28.53 ppm (CH3).
3,9-Bis(2-oxo-3,6-diazahexyl)-6-carboxymethyl-3,6,9-triazaundecanedioic
acid (6): Asolution of 5 (2.50 g, 3.69 mmol) in pure trifluoroacetic acid
(10 mL) was stirred for 12 h. The solvent was removed under reduced
pressure, followed by addition and then evaporation of CH2Cl2 (3
10 mL) then ether (10 mL). The residue was taken up in water, filtered,
and lyophilized to give 6 (2.94 g, 97%) as a white solid. 1H NMR
(300 MHz; D2O; pH 1): d=4.14 (s, 4H; CH2CO), 4.11 (s, 4H; CH2CO),
3.80 (s, 2H; CH2CO), 3.62 (t, 4H; CH2N), 3.55 (t, 4H; CH2N), 3.30 (t,
4H; CH2N), 3.22 ppm (t, 4H; CH2N); 13C NMR (300 MHz; D2O; pH 1):
d=174.48 (CO), 171.94 (CO), 169.80 (CO), 57.95 (CH2N), 57.43 (CH2N),
55.58 (CH2N central), 54.15 (CH2N), 51.95 (CH2N), 40.53 (CH2N),
38.61 ppm (CH2N).
N-(4,5-Dihydro-1H-imidazol-2-yl)-nitrilo-2,2’,2’’-triethanamine (3): Com-
pound 2 was redissolved in EtOH (20 mL), then HCl (20 mL, 37%) was
added dropwise. This solution was stirred at RT for 1.5 h. The solvent
was removed under reduced pressure. MeOH (6100 mL) was added
and then evaporated from the solution. The yellow foam obtained was
dissolved in a minimum amount of a methanol/water mixture and the
product was isolated by cation exchange chromatography on a DOWEX
50-W8–200 (H+ form) column. An elution gradient from 20 to 50%
HCl (37% aq) in methanol was used. The solvent was removed under re-
duced pressure and the residue was taken up in water, then lyophilized.
The HCl salt of 3a (6.629 g, 87%) was obtained as a white powder.
1H NMR (400 MHz; D2O): d=3.72 (s, 4H; CH2 imidaz), 3.42 (t, 2H;
CH2), 3.08 (t, 4H; CH2), 2.80 (t, 4H; CH2), 2.74 ppm (t, 2H; CH2);
13C NMR (300 MHz; D2O): d=161.54 (CN3), 53.10 (CH2), 51.71 (CH2),
44.41 (CH2), 40.72 (CH2), 37.74 ppm (CH2).
3,9-Bis[3-(dihydroxoboranylphenyl)-2-oxo-3,6-diazaheptyl]-6-carboxy-
methyl-3,6,9-triazaundecanedioic acid (L2): Asolution of
6 (2.94 g,
3.59 mmol), 3-formylphenylboronic acid (1.38 g, 9.20 mmol), and triethyl-
amine (8.0 mL) in methanol (15 mL) was stirred at room temperature for
2 h. NaBH4 was added carefully (1.39 g, 36.7 mmol). The resulting so-
lution was stirred at RT for 12 h. The solvent was removed under re-
duced pressure and the residue was taken up in water (ca. 10 mL). The
resulting suspension was filtered and the desired product was recovered
from the solution by cation exchange chromatography on a DOWEX 50-
W8–200 (H+ form) column. The column was washed with water, then
the product was eluted with an aqueous ammonia solution (8%). The
solvent was removed under reduced pressure. The residue was taken up
in water and lyophilized to give L2 (2.391 g, 90%) as a white powder.
N-(4,5-Dihydro-1H-imidazol-2-yl)-N’-(2-dihydroxyboranylphenyl)-nitrilo-
2,2’,2’’-triethanamine (4): Intermediate 3 (4.07 g, 12.56 mmol) was dis-
solved in a minimum amount of methanol/triethylamine (3:1 v/v, ca.
70 mL). Asolution of 2-formylphenylboronic acid (1.88 g, 12.56 mmol) in
the same solvent (320 mL) was added dropwise over 30 min. The mixture
was stirred at room temperature for 6 h. The solvent was removed under
reduced pressure and the residue was redissolved in methanol (100 mL).
NaBH4 (2.38 g, 62.9 mmol) was added carefully. The reaction mixture
was stirred overnight, then the solvent was removed under reduced pres-
sure. The residue was taken up in water (ca. 15 mL) and filtered. The
product was isolated by cation exchange chromatography on an Amber-
1
11B NMR (400 MHz; D2O; pH 11.3): d=ꢁ16.6 ppm; H NMR (300 MHz;
D2O; pH 11.3; T=808C): d=7.50–7.60 (brs, 4H; ArH), 7.52 (brs, 2H;
ArH), 7.18–7.25 (brs, 2H; ArH), 3.78 (s, 4H; ArCH2), 3.41 (t, 4H;
CH2N), 3.29 (s, 4H; CH2CO), 3.21 (s, 4H; CH2CO), 3.15 (s, 2H;
CH2CO), 2.81 (t, 4H; CH2N), 2.75 ppm (brs, 8H; CH2N); 13C NMR
(300 MHz; D2O; pH 11.3; T=808C): d=179.7 (CO), 175.7 (CO), 175.5
(CO), 138.6 (C), 132.3 (C), 131.1 (C), 128.2 (C), 127.0 (C), 126.7 (C), 60.1
(CH2), 59.5 (CH2), 59.1 (CH2), 53.5 (CH2), 52.9 (CH2), 47.8 (CH2), 39.4
(CH2), 30.7 ppm (CH2). ESI-MS (positive): m/z: 748.62 [M+3]+
+
lite CG50 (NH4 form) column with an elution gradient from 50 mm to
2m NH4OH in water. The fractions containing the desired product were
collected and lyophilized to give the carbonate salt of
4 (1.450 g,
Preparation of the Gd3+ complexes: Complexation was carried out by
addition of stoichiometric amounts of GdCl3 to aqueous solutions of the
ligands under weakly acidic conditions (5.5<pH<6.5) at room tempera-
ture. The formation of the complex was monitored by measuring the sol-
vent proton relaxation rate (1/T1). The small excess of free Gd3+ ions,
which yielded a noticeable increase in the observed relaxation rate, was
removed by centrifugation of the solution after adjustment to basic pH.
3.25 mmol, 26%) as a pale yellow fluffy solid. 1H NMR (300 MHz; D2O;
pH<2): d=7.71–7.76 (m, 1H; ArH), 7.38–7.51 (brs, 3H; ArH), 4.33 (s,
2H; ArCH2), 3.56 (s, 4H; CH2 imidaz), 3.32 (t, 2H; CH2), 3.27 (t, 2H;
CH2), 3.01–3.20 (brs, 6H; CH2), 2.92 ppm (t, 2H; CH2); 13C NMR
(300 MHz; D2O; pH 7): d=161.49 (CN3), 139.26 (Carom), 134.39 (Carom),
131.36 (Carom), 130.05 (Carom), 129.47 (Carom), 54.21 (CH2), 52.96 (CH2),
51.91 (CH2), 51.07 (CH2), 45.66 (CH2), 44.28 (CH2 imidaz), 41.37 (CH2),
Chem. Eur. J. 2004, 10, 5205 – 5217
ꢀ 2004 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
5215